Pre-Surgical PET MRI Scan for Retroperitoneal Sarcoma
(PET-RPS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the use of PET MRI scans to predict how well a rare cancer called retroperitoneal sarcoma responds to chemotherapy before surgery. Researchers aim to determine if PET imaging can reveal early tumor changes, enabling doctors to adjust the treatment plan sooner if necessary. The trial seeks participants with a specific type of untreated retroperitoneal sarcoma who are eligible for chemotherapy and surgery and have not received prior cancer treatment in the abdomen or pelvis. As an unphased trial, this study offers patients the chance to contribute to groundbreaking research that could lead to more personalized treatment strategies.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor to get specific guidance based on your situation.
What prior data suggests that this PET MRI scan is safe for patients with retroperitoneal sarcoma?
Research has shown that PET MRI scans are generally safe and manageable for patients. One study found that PET MRI can detect returning soft tissue sarcomas, a type of cancer, more effectively than MRI alone. This indicates that PET MRI is reliable and poses no major risks for patients. Another study discovered that PET MRI was more accurate than PET CT in many cancer cases, achieving a high accuracy rate of 97.3%. This suggests the technology is both effective and safe for cancer imaging. No specific reports have linked negative effects directly to PET MRI scans, which is reassuring for those considering this imaging as part of a clinical trial.12345
Why are researchers excited about this trial?
Researchers are excited about using PET MRI scans for retroperitoneal sarcoma because this imaging technique offers a more detailed view of both the structure and function of tumors. Unlike the standard PET-CT scans, which primarily give structural information, PET MRI provides better soft tissue contrast and can help distinguish between different types of tissues more accurately. This could lead to better treatment planning by providing clearer insights into the tumor's characteristics and response to chemotherapy, potentially improving patient outcomes.
What evidence suggests that PET MRI is effective for assessing early response to treatment in retroperitoneal sarcoma?
Research has shown that PET scans effectively assess how retroperitoneal sarcoma (RPS) responds to treatment. Some studies found that PET scans excel at detecting cancer cells in RPS patients, enabling early detection. In this trial, participants will undergo a PET-MR scan, which combines PET with MRI, at baseline and after one chemotherapy cycle. This approach is being tested as a potentially faster and more effective way to monitor RPS response to chemotherapy compared to traditional imaging methods like CT scans. PET scans are already used for other cancer types to evaluate treatment effectiveness before changes appear in regular scans. This early detection helps doctors quickly adjust treatment plans, potentially improving patient outcomes.678910
Who Is on the Research Team?
Carol Swallow, MD, PhD
Principal Investigator
Sinai Health System
Are You a Good Fit for This Trial?
Adults over 18 with a specific type of large abdominal cancer called high-grade Retroperitoneal Sarcoma (RPS), who haven't had previous treatments. They must have a single tumor that's operable and suitable for chemotherapy, good overall health without serious heart, kidney, liver or blood conditions, no other cancers in the last 5 years except certain skin or cervical cancers, and be able to follow the study plan.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
PET-MR and PET-CT scans are performed to establish baseline measurements
Chemotherapy Treatment
Participants receive ifosfamide/doxorubicin chemotherapy every 3 weeks for 5-6 cycles
PET-MR Assessment
PET-MR scan is performed after 1 cycle of chemotherapy to assess early response
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PET MRI scan
Trial Overview
The trial is testing if PET MRI scans can detect early responses to preoperative chemotherapy in patients with RPS better than conventional CT scans. This could allow doctors to adjust treatment plans sooner for better outcomes.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Every eligible patient will be scanned by PET-MR at baseline and following 1 cycle of chemotherapy. PET-CT at baseline will also be obtained as it is the current standard of care and will be used to determine trial eligibility (no evidence metastasis at baseline).
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Citations
Value of PET scan in patients with retroperitoneal sarcoma ...
A malignant diagnosis was confirmed in all patients who underwent CT-guided core biopsy; a diagnosis of sarcoma was reached in 91%. Sensitivity of FDG-PET ...
CT and MR Imaging of Retroperitoneal Sarcomas
This article provides an overview of the current knowledge regarding cross-sectional imaging features of patients with retroperitoneal sarcomas.
NCT04224948 | The PET- Retroperitoneal Sarcoma Study
This study will focus on improving the outcomes of surgery by treating RPS before surgery, to make resection more effective.
The Role of Preoperative 18F-fluorodeoxyglucose Positron ...
In retroperitoneal sarcoma (RPS), the effectiveness of PET was not well known. ... Outcomes Following Extended Surgery for Retroperitoneal Sarcomas: Results ...
Value of PET scan in patients with retroperitoneal sarcoma ...
A malignant diagnosis was confirmed in all patients who underwent CT-guided core biopsy; a diagnosis of sarcoma was reached in 91%. Sensitivity of FDG-PET ...
Imaging in retroperitoneal soft tissue sarcoma - PMC
Core needle biopsy of a retroperitoneal sarcoma (RPS) is safe, reliable and must be strongly recommended unless the imaging is pathognomonic of a ...
Primary retroperitoneal soft tissue sarcoma: Imaging ...
Failure to recognise retroperitoneal sarcomas on imaging can lead to inappropriate management in inexperienced centres. This can have catastrophic consequences ...
Applications of PET-MRI in Musculoskeletal Disease - PMC
Integrated PET-MRI has been recently shown to have benefit compared to MRI alone for the identification of locally recurrent soft tissue sarcomas. In a study of ...
PET/MRI in Oncological Imaging: State of the Art
PET/MRI is a promising new modality which may replace PET/CT in selected cancer scenarios and may generate new oncological applications.
PET/MRI versus PET/CT in oncology: a prospective single- ...
PET/MRI was accurate in 319/330 examinations and PET/CT in 277/330 examinations; the respective accuracies of 97.3% and 83.9% differed ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.